sitagliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Mechanism: Dipeptidyl peptidase IV inhibitor.
- Mechanism
- Dipeptidyl peptidase IV inhibitor
pharma · Type 2 Diabetes
Chen Suning
Chen Suning drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Chen Suning pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Chen Suning drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.
- Target
- Dipeptidyl peptidase 4
- Mechanism
- Dipeptidyl peptidase IV inhibitor